

OsteoTest: At Home Osteoporosis Test

Clara Cheung, Alix Dixon-Ernst, Aditi Gogineni, Travis Horst, Marcia Solorzano, Jia Jia Zhang Dr. James Antaki, Dr. Alberto Gandini, Dr. Conrad Zapanta

Executive Summary

Osteoporosis is a widespread problem with increasing cases as baby boomers increase in age. Injuries due to falling have costs in excess of \$17 billion associated with them and cause significant quality of life issues for elderly patients. Having a more convenient method of testing for osteoporosis will increase early detection and decrease associated costs of the disease. Our device will use a small blood sample to detect alkaline phosphatase levels, which will be correlated to bone turnover rates in patients. An immunoassay with magnetic beads will be encapsulated in a disposable device that will be cheap, portable and easy to use for elderly patients. Current methods, such as DEXA scans, are expensive, must occur in a doctor's office and are time consuming. Our device will improve upon all of these areas.

Problem and Clinical Need

- Osteoporosis is the loss of bone density by which the bones lose optimal mass and strength.
- Can occur due to excessive bone reabsorption and inadequate response to increased bone reabsorption
- Diagnosis of the disease allows preventative treatment to save money and increase quality of life.
- While osteoporosis cannot be cured, it can be retarded by: exercise, diet and medicine.
- Design Requirements: Affordable, Accurate, Portable, Ease of Use and Clear Readout

Market Analysis

- Currently affects over 14 million Americans, another 47 million are at high risk and 5 million have fractures due to Osteoporosis.
- Affects I in 3 women and I in 5 men.
- This number will only continue to grow as the generation of baby boomers becomes older.
 - ♦ Estimated that by 2020, bone loss will affect 60 million citizens over 50^[1].
- Total costs including prevalent fractures are more than \$19 billion.
- Current Standards: DEXA scan and an X-Ray.
 - \diamond X-Ray scans are not as precise
 - DEXA scans are expensive and time consuming



device and magnet (inside casing)

Figure I: CAD model of casing design

Casing Design (Figure | & 2)

- Casing designed using CAD
- · Casing constructed via Rapid
- **3D** Prototyping Top locks into bottom using
- a snapping mechanism Magnet is housed internally

in the casing

- Sandwich ELISA Binding chamber is coating in **BALP** antibody
- ALP enters binding chamber
- ALP is captured by BALP antibody and remains within
- binding chamber Magnetic beads coated with
- another form of BALP antibody enter binding chamber Magnetic beads bind to ALP
- Excess beads are washed through binding chamber to readout chamber




Figure 3: Working prototype with coated binding chamber and readout chambe

Device Design (Figure 3) · Device is made of two parts: binding

- chamber and readout chamber · Both chambers are laser cut from
- polyethylene glycol (PEG) · Readout chamber is laminated to seal
- Binding chamber is coated and covered
- with a thin PEG cover sheet with inlet and outlet ports

YYYYYYYYY ← Immobilized BALP antibody PEG

Figure 4: Un-used coated binding chamber

Y Y Y Y Y Y Y Y Y X X Alkaline phosphatase Immobilized BALP antibody

Figure 5: ALP captured in binding chamber

Magnetic beads with BALP

← antibody

PEG Figure 6: Completed sandwich ELISA in binding chamber using etic heads

What is Novel About the Device?

- Measures bone turnover rate using Alkaline Phosphatase biomarker. Small and portable hand-held at-home test.
- Ease-of-use in terms of self pricking and magnified readout. Disposable.
- Affordable and available to a large population

Estimation of Product Costs

OsteoTest is estimated to cost \$2.67 per device (without Cost of Machinery)

- Cost of Machinery is \$10,000 (one time purchase)
- Cost of Unit at Bulk
 - ♦ 10,000 Units \$3.70 per device ♦ 100,000 Units- \$2.77 per device

Profit

- Product Selling Base Price- \$10 per device ♦ Profit per 10,000 Units- \$63,000
- ♦ Profit per 100,000 Units- \$723,000

Anticipated Regulatory Pathway

Class II medical device

- Novel device; no predicate device exists in market
- Require Premarket Approval (PMA)
- Needs valid scientific evidence; target post-menopausal women Must be reviewed by CBER
- Blood samples from human clinical studies determines accuracy
- Blood samples from animal studies proves functionality

Acknowledgements

We would like to thank Dr. Conrad Zapanta and Dr. James Antaki for advising our project. We would also like to acknowledge Abhinav Singhal for his guidance. In addition, we would like to thank Dr. Alberto Gandini and Ipek Sarioglu for lab space and support. We would also like to thank Dr. Joseph Ahern for being a clinical contact.